Marta Cipriani

About me

Hi! Welcome to my webpage.
I am Marta Cipriani, a postdoctoral researcher in Statistics at the School of Mathematics and Statistics of University College Dublin.

I am currently working on a project funded by VistaMilk on innovative statistical and chemometric methods for high-dimensional, agri-food data.

My research so far has focused on survival analysis, with particular interest in:

• mixture cure models
• dynamic prediction and landmarking
• multiple imputation for missing data
• synthetic data generation for clinical trials

Previously, I completed my PhD in Methodological Statistics at Sapienza University of Rome, worked as a research fellow at Roma Tre University, and was a visiting PhD student at the Mathematical Institute of Leiden University. I have been involved in research projects on clinical trial methodology and real-world data analysis, in collaboration with the GIMEMA Foundation.

I am also actively involved in the Computational Intelligence Methods for Bioinformatics and Biostatistics (CIBB) conference series.
I will serve as General Chair of CIBB 2026, which will take place in Rome on September 2-4, 2026.
More information is available on the official conference website: http://cibb2026.teralab.ai/

If you would like to know more on me, you can find my CV here.

Publications

Scientific papers

• Cipriani M, Alfò M, Signorelli M. Dynamic prediction in mixture cure models: a model-based landmarking approach. arXiv, 2025+ (link)
• Cipriani M, Fiocco M, Alfò M, Quelhas M, Musta E. A multiple imputation approach to distinguish curative from life‑prolonging effects in the presence of missing covariates. arXiv, 2025+ (link)
• Cipriani M, Di Rocco L, Puopolo M, Alfò M. A flexible parametric approach to synthetic patients generation using health data. Statistical Methods and Applications, 2025 (link)
• Campanale A, Ventimiglia M, Alfò M, Cipriani M, Minella D, Lispi L, Iachino A. Current knowledge on breast implant‑associated anaplastic large cell lymphoma: Evidence from Italian Ministry of Health Registry Data. Aesthetic Plastic Surgery, 2025 (link)
• Tadesse F, Sparano F, Gebremedhin A, Abubeker A, Piciocchi A, Cipriani M, et al. Health-Related Quality of Life and Financial Burden in Ethiopian Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Study. JCO Global Oncology, 2024 (link)
• Efficace F, Mahon F-X, Richter J, Piciocchi A, Cipriani M, et al. Health‑related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO‑SKKI Trial. Leukemia, 2024 (link)
• Piciocchi A, Cipriani M, Messina M, Marconi G, Arena V, et al. Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients. eJHaem, 2023 (link)
• Lombardo FL, Spila Alegiani S, Mayer F, Cipriani M, et al. A randomized double-blind clinical trial on safety and efficacy of TUDCA as add-on treatment in ALS: the statistical analysis plan of TUDCA-ALS trial. Trials, 2023 (link)
• Cipriani M, Pichiorri F, Colamarino E, Toppi J, Tamburella F, Lorusso M, et al. The Promotoer, a brain-computer interface-assisted intervention to promote upper limb functional motor recovery after stroke: a statistical analysis plan. Trials, 2023 (link)
• Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, et al. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. Blood Adv, 2023 (link)

Proceedings

• Cipriani M, Fiocco M, Alfò M, Musta E. Missing Covariates in Mixture Cure Models: A Multiple Imputation Approach. Statistics for Innovation II, 2025 (link)
• Cipriani M, Di Rocco L, Alfò M. A Flexible Parametric Approach to Synthetic Patients Generation in Clinical Trials. Methodological and Applied Statistics and Demography III, 2025 (link)
• Piciocchi A, Messina M, Marsili G, Cipriani M, et al. Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph‑Negative ALL. Blood, 2024 (link)
• Piciocchi A, Chiaretti S, Cipriani M, Messina M, et al. A Propensity Score Weighting Analysis Emphasizes the Progress of the Gimema Approach in Adult Ph-Positive Acute Lymphoblastic Leukemia in the TKI Era. Blood, 2023 (link)
• Attardi E, Savi A, Borsellino B, Cipriani M, Piciocchi A, et al. Unraveling the Impact of 2022 Classifications on Secondary Acute Myeloid Leukemia: Assessing the True Qualification Power of Diagnostic Qualifiers. Blood, 2023. (link)
• Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, et al. P499: Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. HemaSphere, 2023. (link)
• Efficace F, Mahon F-X, Richter J, Piciocchi A, Cipriani M, et al. S159: Health-related quality of life of patients with chronic myeloid leukemia after discontinuation of tyrosine kinase inhibitors: Results from the EURO-SKI study. HemaSphere, 2023 (link)
• Piciocchi A, Marconi G, Cipriani M, et al. P523: The comparison of VFLAI, FLAI and 3+7 regimens by multilevel propensity score weighting highlights the benefit of the addition of venetoclax in no low-risk AML treated in GIMEMA trials and real world. HemaSphere, 2023 (link)
• Piciocchi A, Cipriani M, Messina M, Marconi G, et al. P495: Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience. HemaSphere, 2023 (link)
• Martinelli G, Cipriani M, Marconi G, Guolo F, Minetto P, Paoloni F, Cotugno F, et al. Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: A GIMEMA Italian cooperative analysis. Journal of Clinical Oncology, 2023 (link)
• Cipriani M, Piciocchi A, Arena V, Alfò M. Pseudo-observations in survival analysis. Book of short papers SIS 2023 - Statistical Learning, Sustainability and Impact Evaluation, 2023 (ISBN: 9788891935618)
• Piciocchi A, Messina M, Cipriani M, Paoloni F, et al. The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials. Blood, 2022 (link)
• Tadesse F, Gebremedhin A, Abubeker A, Piciocchi A, Cipriani M, et al. Health-Related Quality of Life and Financial Burden of Ethiopian Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors. Blood, 2022 (link)

Awards

• Best Poster Award, International Workshop on Statistical Modelling, Limerick, Ireland, 2025
• Best Poster Award, Survival Analysis for Junior Researchers Conference, Bonn, Germany, 2025
• Best Oral Paper Presentation, International Biometric Conference, Atlanta, USA, 2024

Contact

University College Dublin
School of Mathematics and Statistics
Science Centre - North
Belfield Dublin 4

You can write me at marta.cipriani@ucd.ie

• GitHub
• LinkedIn
• Google Scholar

Elements

i = 0;

while (!deck.isInOrder()) {
    print 'Iteration ' + i;
    deck.shuffle();
    i++;
}

print 'It took ' + i + ' iterations to sort the deck.';